What's Happening?
Bristol Myers Squibb (BMY) has been identified as a more reliable dividend stock for retirees compared to General Mills (GIS), despite offering a lower current yield. According to TIKR and StockAnalysis data, Bristol Myers Squibb has a 4.1% dividend yield with
a cash dividend payout ratio of 55% over the past twelve months to September 30, 2026. In contrast, General Mills offers a higher 7.2% yield but has a significantly stretched payout ratio of 85% over the same period, leading Piper Sandler to warn of a potential dividend cut. Bristol Myers Squibb's third-quarter revenue increased by 7% to $13.1 billion, with its Growth Portfolio rising 12% to $7.7 billion, driven by products like Opdivo Qvantig, Breyanzi, and Camzyos. The company also raised its 2026 revenue guidance to $49.75 billion to $50.25 billion.
Why It's Important?
This assessment is crucial for retirees and income-focused investors in the U.S. seeking stable dividend income. The reliability of a dividend is often prioritized over its immediate yield, especially for those dependent on regular payouts. Bristol Myers Squibb's lower payout ratio and strong revenue growth from its 'Growth Portfolio' indicate a healthier financial position to sustain and potentially grow its dividend. Conversely, General Mills' high payout ratio and flat organic net sales raise concerns about the long-term sustainability of its dividend, despite management's commitment to it. The potential for a dividend cut at General Mills, as estimated by Piper Sandler, could significantly impact retirees' financial planning, making Bristol Myers Squibb a more secure option for consistent income.
What's Next?
Bristol Myers Squibb is expected to continue its commitment to its dividend, as stated by CFO David Elkins, while also prioritizing business development. The company anticipates a decline in Eliquis revenue by $1.5 billion to $2 billion in 2027, which means the continued growth of its newer drugs will be essential to offset this. For General Mills, the focus will be on deleveraging, with management expecting it to take at least a couple of years to reach its target of 3x net debt to EBITDA. Until then, its dividend is likely to remain flat at best. Investors will closely monitor the financial performance and strategic decisions of both companies, particularly regarding their ability to generate free cash flow and manage debt, which will directly impact their dividend policies.
Beyond the Headlines
The comparison between Bristol Myers Squibb and General Mills highlights a fundamental principle in dividend investing: the importance of financial health and sustainability over a high headline yield. While a high yield can be attractive, a company's ability to cover its dividend payments with free cash flow and manage its debt levels are critical indicators of long-term reliability. This scenario also underscores the challenges faced by companies in mature industries, like consumer staples (General Mills), compared to those in growth-oriented sectors, like biopharmaceuticals (Bristol Myers Squibb), which can leverage innovation for revenue expansion. For retirees, understanding these underlying financial metrics is paramount to making informed investment decisions that secure their income streams and overall financial well-being.













